| Basics |
MacroGenics, Inc.
Macrogenics Inc is a clinical-stage biopharmaceutical company. It focusses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases.
|
| IPO Date: |
October 10, 2013 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$86.66M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.48 | 3.08%
|
| Avg Daily Range (30 D): |
$0.05 | 3.27%
|
| Avg Daily Range (90 D): |
$0.06 | 3.68%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.56M |
| Avg Daily Volume (30 D): |
.99M |
| Avg Daily Volume (90 D): |
.81M |
| Trade Size |
| Avg Trade Size (Sh.): |
108 |
| Avg Trade Size (Sh.) (30 D): |
198 |
| Avg Trade Size (Sh.) (90 D): |
196 |
| Institutional Trades |
| Total Inst.Trades: |
2,276 |
| Avg Inst. Trade: |
$1.67M |
| Avg Inst. Trade (30 D): |
$.69M |
| Avg Inst. Trade (90 D): |
$.65M |
| Avg Inst. Trade Volume: |
.1M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.72M |
| Avg Closing Trade (30 D): |
$.63M |
| Avg Closing Trade (90 D): |
$.59M |
| Avg Closing Volume: |
112.08K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-1.2
|
$.27
|
$-.57
|
|
Diluted EPS
|
$-1.2
|
$.27
|
$-.57
|
|
Revenue
|
$ 127.63M
|
$ 72.84M
|
$ 22.24M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -75.89M
|
$ 16.82M
|
$ -36.25M
|
|
Operating Income / Loss
|
$ -113.58M
|
$ 18.64M
|
$ -36.76M
|
|
Cost of Revenue
|
$ .23M
|
$ M
|
$ M
|
|
Net Cash Flow
|
$ -99.5M
|
$ -50.56M
|
$ -14.88M
|
|
PE Ratio
|
|
|
|
|
|
|
